4-Tert-butyl-4-azaspiro[2.4]heptane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-Tert-butyl-4-azaspiro[2.4]heptane
• 英文别名: 4-tert-butyl-4-azaspiro[2.4]heptane
• 化学式: C₁₀H₁₉N
• 分子量: 153.26
• InChiKey: MKZPFKHWOGXPBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20160046654A1

  公开（公告）日：2016-02-18

  Provided are prodrugs of a bicyclic substituted pyrimidine type PDE-5 inhibitors, pharmaceutically acceptable salts or stereoisomers thereof. Also provided are methods for preparing these prodrug compounds, pharmaceutical preparations, and pharmaceutical compositions, as well as a use of these compounds, pharmaceutical preparations and pharmaceutical compositions in the manufacture of medicaments for treatment and/or prophylaxis of sexual dysfunction and lower urinary tract symptoms.

  提供了一种双环替代嘧啶型PDE-5抑制剂的前药，其药用盐或立体异构体。还提供了制备这些前药化合物、制药制剂和制药组合物的方法，以及这些化合物、制药制剂和制药组合物在制造用于治疗和/或预防性功能障碍和下尿路症状的药物中的用途。
• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
  申请人：Zhang Hui

  公开号：US20140179638A1

  公开（公告）日：2014-06-26

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R 2a , R 2b , R 3 , R 4a , R 4b , R 5 , R 6a , R 6b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , R 12 , R 13a and R 13b are each independently as defined in the description.

  本发明涉及由式(I)表示的9-氨甲基取代四环素化合物，或其药学上可接受的盐、前药、溶剂化合物或异构体，以及制备这些化合物的方法和包含其的药物组合物。本发明还涉及这些化合物在制备用于治疗和/或预防四环素药物敏感疾病的药物中的用途。其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a和R13b各自独立地如描述中所定义。
• QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Wu Frank

  公开号：US20140161801A1

  公开（公告）日：2014-06-12

  The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R 1 , R 2 , R 3 , R 3′ , R 4 , R 5 , R 6 , X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.

  该发明涉及一种喹唑啉衍生物，其通式表示为(I)，作为酪氨酸激酶抑制剂的药用可接受盐和立体异构体，其中R1、R2、R3、R3'、R4、R5、R6、X、L、T、Z和q如规范中所定义。该发明还涉及一种制备该衍生物的方法，包含该衍生物的药用组合物和药用配方，以及将该衍生物用于治疗过度增殖性疾病和慢性阻塞性肺病，以及将该衍生物用于制造用于治疗过度增殖性疾病和慢性阻塞性肺病的药物。
• Heterocyclic Substituted Pyrimidine Compound
  申请人：Wu Yongqian

  公开号：US20140288063A1

  公开（公告）日：2014-09-25

  The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.

  本发明涉及医学技术领域，特别涉及一种由通用公式（I）表示的杂环取代嘧啶化合物及其在药学上接受的盐，其中R1、R2、R3、R4和R5如描述中所定义，本发明还涉及该化合物的制备方法、含有该化合物的药物组合物，以及该化合物和药物组合物在制备增强cGMP信号转导功能的药物或治疗或预防性功能障碍和下尿路症状疾病的药物中的用途。
• Bicyclic Substituted Pyrimidine Compounds
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：US20150232474A1

  公开（公告）日：2015-08-20

  Disclosed are bicyclic group substituted pyrimidine compounds, pharmaceutical acceptable salts thereof or stereoisomers thereof. Also disclosed are preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfunction diseases and diseases with lower urinary tract symptoms.

  本发明涉及含有双环基团取代的嘧啶化合物，其药用可接受的盐或立体异构体。本发明还涉及该化合物的制备方法、制药配方和制药组合物，以及使用该化合物、制药配方和制药组合物制备用于治疗和/或预防性功能障碍疾病和下尿路症状的药物。